Welcome to 'tissue therapeutics’: Dave Lennon’s $110M new venture will implant ‘happy cells’ that ‘survive and thrive’
You’ve heard of cell therapies. You’ve certainly heard of gene therapies. But have you heard of tissue therapeutics?
Just in time for May flowers, a biotech two decades in the works — longer if you count the co-founders’ first academic encounters as grad student peers in the mid-1990s — has sprung from the shadows of Cambridge, MA to introduce the world to what it deems an “exciting new pillar within the regenerative medicine field.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.